Affordable Access

Publisher Website

U-IMD: the first Unified European registry for inherited metabolic diseases

  • Opladen, Thomas1
  • Gleich, Florian1
  • Kozich, Viktor2
  • Scarpa, Maurizio3
  • Martinelli, Diego4
  • Schaefer, Franz5
  • Jeltsch, Kathrin1
  • Juliá-Palacios, Natalia6
  • García-Cazorla, Ángels6
  • Dionisi-Vici, Carlo4
  • Kölker, Stefan1
  • 1 Division of Neuropediatrics and Metabolic Medicine, Department of General Pediatrics, Centre for Child and Adolescent Medicine, Im Neuenheimer Feld 430, 69120 Heidelberg, Germany
  • 2 Charles University - First Faculty of Medicine and General University Hospital,
  • 3 Udine University Hospital,
  • 4 IRCCS Ospedale Pediatrico Bambino Gesù,
  • 5 Division of Pediatric Nephrology, Department of General Pediatrics, Centre for Child and Adolescent Medicine, Heidelberg, Germany
  • 6 Inborn Errors of Metabolism Unit, Neurology Department, Institut de Recerca Sant Joan de Déu, and CIBERER-ISCIII, Barcelona, Spain
Published Article
Orphanet Journal of Rare Diseases
Springer (Biomed Central Ltd.)
Publication Date
Feb 18, 2021
DOI: 10.1186/s13023-021-01726-3
PMID: 33602304
PMCID: PMC7893973
PubMed Central


Background Following the broad application of new analytical methods, more and more pathophysiological processes in previously unknown diseases have been elucidated. The spectrum of clinical presentation of rare inherited metabolic diseases (IMDs) is broad and ranges from single organ involvement to multisystemic diseases. With the aim of overcoming the limited knowledge about the natural course, current diagnostic and therapeutic approaches, the project has established the first unified patient registry for IMDs that fully meets the requirements of the European Infrastructure for Rare Diseases (ERDRI). Results In collaboration with the European Reference Network for Rare Hereditary Metabolic Disorders (MetabERN), the Unified European registry for Inherited Metabolic Diseases (U-IMD) was established to collect patient data as an observational, non-interventional natural history study. Following the recommendations of the ERDRI the U-IMD registry uses common data elements to define the IMDs, report the clinical phenotype, describe the biochemical markers and to capture the drug treatment. Until today, more than 1100 IMD patients have been registered. Conclusion The U-IMD registry is the first observational, non-interventional patient registry that encompasses all known IMDs. Full semantic interoperability for other registries has been achieved, as demonstrated by the use of a minimum common core data set for equivalent description of metabolic patients in U-IMD and in the patient registry of the European Rare Kidney Disease Reference Network (ERKNet). In conclusion, the U-IMD registry will contribute to a better understanding of the long-term course of IMDs and improved patients care by understanding the natural disease course and by enabling an optimization of diagnostic and therapeutic strategies.

Report this publication


Seen <100 times